Product Description
Mechanisms of Action: CLDN6 Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Context
Company Location: PHILADELPHIA PA 19104
Company CEO: Martin Lehr
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|